( SAN DIEGO--(BUSINESS WIRE)--Mar 26 200...)Inovio Biomedical's DNA Delivery Technology Significantly Enhances,Potency of HIV DNA Vaccine,Health

SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2007 - Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today that the Journal of Virology has published a scientific paper prepared by Inovio's development partner, Wyeth, regarding results from a non-human primate study of an investigational DNA vaccine against HIV delivered using Inovio Biomedical's electroporation technology. The paper, titled "Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques," summarized results of a research project lead by Michael A. Egan, Ph.D., a principle research scientist at Wyeth Vaccine Research. The scientific paper concluded: "These results indicate that in vivo electroporation appears safe and can dramatically improve the delivery and immunogenicity of a multi-vector, multi-antigen pDNA vaccine in non-human primates. Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Key observations of the study included:

-- Vaccination in combination with in vivo electroporation led to a more rapid onset and enhanced vaccine-specific immune responses.

-- This increase in CMI (cell-mediated immune) responses translates to an apparent 50-200-fold (8 weeks and 22 weeks, respectively) increase in pDNA (plasmid DNA) vaccine potency.

-- Importantly, in vivo electroporation enhanced the immune response against the less immunogenic antigens, resulting in a more balanced immune response.

-- In addition, in vivo electroporation resulted in an approximate 2.5 log10 increase in antibody responses.

"Wyeth's non-human primate data demonstrated a significant increase in both the breadth and magnitude of the cellular immune response to selected HIV antigens
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
3. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
4. Inovio: DNA delivery technology shows positive human results
5. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics